Intracerebroventricular Application of Dexmedetomidine Produces Antinociception and Does not Cause Neurotoxicity in Rats

Ersin Köksal1, Deniz Karakaya1, Bilge Can2, Ayhan Bozkurt3, Sibel Bang1, Süleyman Sırrı Bilge4, Yasemin Burcu Üstün1

1Department of Anesthesiology and Reanimation, Ondokuz Mayis University Faculty of Medicine, Samsun, Turkey
2Department of Pathology, Ondokuz Mayis University Faculty of Medicine, Samsun, Turkey
3Department of Physiology, Ondokuz Mayis University Faculty of Medicine, Samsun, Turkey
4Department of Pharmacology, Ondokuz Mayis University Faculty of Medicine, Samsun, Turkey

ABSTRACT

Background: Alpha2 agonists contribute to pain control at the level of the medulla spinalis. Alpha2 agonists are generally added to local anaesthetics to prolong spinal or epidural anaesthesia time.

Aims: In the present study, we aimed to evaluate the antinociceptive and neurotoxic effects of dexmedetomidine given intracerebroventricularly for 5 days.

Study Design: Animal experimentation.

Methods: After intraventricular cannulation, rats (n=32) were divided into two groups (n=16 each). Rats in the dexmedetomidine group (Group D, n=16) received 3 µg (0.03 mL) dexmedetomidine and the control group (Group C, n=16) received 0.03 mL physiological serum through an intracerebroventricular catheter once a day, for 5 days. Antinociceptive, sedative, and motor effects were evaluated before the injection and for 90 min after injection. The tail-flick and hot plate tests were used to assess thermal nociceptive threshold. For histopathological evaluation, half of the rats in both groups were sacrificed on the 6th day and the remaining rats were sacrificed on the 21st day. Then the perfusion fixation method was applied. The first tissue section was obtained from the cervical spinal cord 1 cm distal to the proximal end of the spinal cord. The second sample was retrieved from the region 1 cm distal from the thoracic 13-lumbar 1 vertebra. On morphological evaluation, nonspecific changes like edema and gliosis, signs of neuronal degeneration demonstrating a severe reaction, and density of inflammatory cells were examined.

Results: In dexmedetomidine-administered rats, on the first day reaction times at 5, 10, and 20 min and on the other days, reaction times at 5, 10, 20, and 30 min in hot plate tests were significantly longer compared with baseline values (p<0.05). In dexmedetomidine-administered rats, on the 1st, 4th, and 5th days reaction times at 5, 10, 20, 30, and 40 min and on the 2nd and 3rd days reaction times at 5, 10, 20, and 30 min in tail-flick tests were significantly longer compared with baseline values (p<0.05). First-degree sedation lasting for 60 min and first-degree motor block lasting for 30–40 min were observed in the dexmedetomidine group. Similar rates of nonspecific changes such as edema and gliosis were seen in both groups. Signs of severe reactions such as neuronal degeneration and diffuse inflammatory cell infiltration were not encountered in any group. There was no significant difference between groups according to morphological findings of the spinal cord on the 6th and 21st days (p>0.05).

Conclusion: We observed that intracerebroventricular administration of 3 µg dexmedetomidine produced antinociception and did not cause neurotoxicity.

Key Words: Dexmedetomidine, analgesia, neurotoxicity

Received: 19.09.2012 Accepted: 31.07.2013

Introduction

Alpha2 agonists contribute to pain control at the level of the medulla spinalis via descendant neuroadrenergic systems originating from the brain. Neuroadrenergic neurons stemming from the locus coeruleus and subcoeruleus nuclei send projections to the posterior horn of the medulla spinalis. Stimulation of this pathway provides antinociception, apparently dependent on noradrenaline discharge (1). Alpha2 agonists are frequently added to local anaesthetics to prolong the duration of spinal or epidural anaesthesia. An alpha2 agonist drug, clonidine, extends the duration of analgesia in patients receiving spinal or epidural anaesthesia when given in combination with local anaesthetics, opioids, or both (2, 3). In studies performed on rats, sedative effects of alpha2 agonists were suggestively related to the alpha2A subtype, which involved the region of the locus coeruleus (4, 5).

Compared with other alpha2 agonists, dexmedetomidine has a higher affinity for receptors, and its spinal antinociceptive efficacy has been demonstrated in animal studies (6, 7). It was reported that long-term intrathecal drug application could induce permanent neuronal damage especially following spinal anaesthesia (8, 9). However, the neurotoxic effects of intrathecal or intracerebroventricular dexmedetomidine application are not known.

In this study, we applied dexmedetomidine via the intracerebroventricular route for 5 days using a different catheterisation technique, with the intention to investigate its antinociceptive, sedative, and neurotoxic effects on the spinal cord.

Material and Methods

This study was performed on 32 16-week-old Wistar strain male rats weighing 250-300 g after obtaining the approval of
the Ethics Committee of Medical and Surgical Research Center, Ondokuz Mayis University Faculty of Medicine. During the study period, all rats had access to water and food ad lib and were kept in cages exposed to alternate 12 hours of dark and light under 21±2°C room temperature. All rats were fasted overnight before the procedure. On the day of the experiment, the rats that were given ketamine (Ketalar, Pfizer, Istanbul, Turkey) anaesthesia (100 mg/kg) via the intraperitoneal (i.p.) route were fixed on a stereotactic surgical apparatus (Stoelting Inc., IL, USA). Then, as described by Paxinos and Watson (10), a burr hole was opened 1.1 mm posterior and 1.5 mm lateral to the bregma, and a stainless steel catheter was inserted into the cranium and advanced deeply for 3.5 mm. After observing the outflow of cerebrospinal fluid from the catheter lumen, it was fixed and immobilised with dental acrylic resin and its external end was closed with a plastic plug. For prophylaxis, all rats were given 30 mg/kg ampicillin i.p.

**Experimental design**

The rats were randomly allocated into two groups 3 days after catheterisation. Rats in the dexmedetomidine group (Group D, n=16) received 3 µg (0.03 mL) dexmedetomidine (Precedex; Hospira, 100 µg/mL); the control group (Group C, n=16) received 0.03 mL physiological serum through an intracerebroventricular catheter once a day, for 5 days. Rats displaying abnormal posture, motor deficit, infection, and impaired health state were excluded from the study.

Nocturnal, motor function, and sedation assessment tests were applied for 5 days between 9 AM and 5 PM, before and after injections in a random fashion every day. Pre-injection values were recorded as baseline, and post-injection values were recorded as test variables.

**Nociceptive evaluation**

Thermal stimulation models were used.

**Hot plate test (supraspinal pain test):** The test was performed according to the method described by Eddy and Leimbach (11). Reaction times of the rats placed on a hot metal plate apparatus with a thermostat that kept the temperature of the plate at 55±0.5°C (Ugo Basile, Thermal PlantarTM, Verona, Italy) were recorded. Jumping, licking, or withdrawing of the hind paws were accepted as a positive reaction. The time interval between placing the rat on the hot plate and the first sign of a positive reaction was also recorded. To prevent tissue damage, rats were left on the hot plate for 60 seconds at most.

**Tail-flick test (spinal pain test):** The test was performed according to the method described by D’Amour and Smith (12). The tail of the rat was half dipped in a water tank with a stable temperature of 55±0.5°C. Tail flick or an audible reaction was accepted as a positive reaction, and the time interval between immersion of the tail and the first sign of a positive reaction was recorded. To prevent tissue damage, the duration of the tail-flick test was limited to 15 seconds.

Latencies (reaction times) measured during hot plate and tail-flick tests were compared with baseline values to calculate the percentage of maximum possible effect (MPE):

\[
\text{MPE} \% = 100 \times \left(\frac{\text{test value} - \text{baseline value}}{\text{cut-off time} - \text{baseline value}}\right)
\]

**Sedation level:** Based on the severity of reactions induced by vocal and tactile stimuli, the degree of sedation was evaluated between 0 and 2 (0=active, 1=tendency to sleep, response to stimuli; 2=sleepy, no response to stimuli) (13).

**Motor function:** Stepping and righting reflexes were evaluated using the Yamamoto scoring system (14). The responses obtained during these tests ranged between 0 and 2 (0=no motor response; 1=slower than normal motor response; 2=normal motor response).

**Histopathological evaluation**

Half of the rats in both groups (eight rats from each group) were sacrificed on the 6 th day and the remaining rats (eight rats from each group) were sacrificed on the 21st day after intracerebroventricular injection, and then the perfusion fixation method was applied with 10% formaldehyde. For histopathological evaluation, laminectomies were performed to extract the medulla spinalis of the rats. The first tissue section was obtained from the cervical spinal cord 1 cm distal to the proximal end of the spinal cord. The second sample was retrieved from the region 1 cm distal from the thoracic 13-lumbar 1 vertebra, corresponding to the last rib of the rat. All tissue samples were embedded in paraffin blocks. From each paraffin block, four pieces of 8-µm thick sections were obtained, stained with haematoxylin-eosin, and evaluated under a light microscope by a pathologist blinded to the study design.

On morphological evaluation, nonspecific changes like edema and gliosis, signs of neuronal degeneration demonstrating a severe reaction, and density of inflammatory cells were examined. Using a scoring system described by Koizumi et al. (15), each histomorphological parameter was scored numerically as 0, 1, and 2 points, and the degree of destructive changes was interpreted based on the total score. Total scores were recorded as nonspecific (0-3 points), mild (4-6 points), and markedly severe (7-10 points) changes.

**Statistical analysis**

Data were transferred into the SPSS 13.0 software package. Wilcoxon test was used for comparison of repeated measures during hot plate and tail-flick tests, and Mann-Whitney U test was used for intergroup comparison of MPE values. For qualitative data of histopathological evaluations, Fisher’s exact test was applied. Data are expressed as median (min-max) and percentages. \(p<0.05\) was considered statistically significant.

**Results**

Two rats were excluded from the study on the second day of experiments because of deterioration in general health state such as lassitude and rejection of being fed. In dexmedetomidine-administered rats, reaction times at 5, 10, and 20 min on the first day and reaction times at 5, 10, 20, and 30 min on the other days in hot plate tests were significantly longer compared with baseline values (\(p<0.05\)) (Table 1). In addition,
reaction times at 90 min on the first day, at 60 min on the second day, at 40, 60, and 90 min on the third day, and at 90 min on the fifth day in hot plate tests were significantly shorter compared with baseline values (p<0.05) (Table 1).

In dexmedetomidine-administered rats, reaction times at 5, 10, 20, 30, and 40 min on the first, fourth, and fifth days and reaction times at 5, 10, 20, and 30 min on the second and third days in tail-flick tests were significantly longer compared with baseline values (p<0.05) (Table 2).

The percentage of MPE in hot plate and tail-flick tests were significantly longer at all times in dexmedetomidine-administered rats compared with the control group (p<0.05). First-degree sedation lasting for 60 min was observed in all rats in the dexmedetomidine group. Sedation was not observed in the control group. First-degree block lasting for 30-40 min in stepping and righting reflexes were observed in all rats in the dexmedetomidine group. No reflex loss was observed in any rat in the control group.

### Table 1. Hot plate test reaction times (in sec) for 5 days in dexmedetomidine-administered rats

<table>
<thead>
<tr>
<th>Day</th>
<th>Baseline</th>
<th>5 min</th>
<th>10 min</th>
<th>20 min</th>
<th>30 min</th>
<th>40 min</th>
<th>60 min</th>
<th>90 min</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>median (min-max)</td>
<td>median (min-max)</td>
<td>median (min-max)</td>
<td>median (min-max)</td>
<td>median (min-max)</td>
<td>median (min-max)</td>
<td>median (min-max)</td>
<td>median (min-max)</td>
</tr>
<tr>
<td>1</td>
<td>7.45 (6.25-8.60)</td>
<td>14.00 (6.00-20.70)</td>
<td>13.95 (9.90-20.00)</td>
<td>12.90 (10.70-14.50)</td>
<td>8.95 (5.10-11.50)</td>
<td>7.00 (5.00-9.70)</td>
<td>6.80 (5.20-7.90)</td>
<td>6.65 (5.00-7.80)</td>
</tr>
<tr>
<td>2</td>
<td>8.87 (6.00-10.20)</td>
<td>16.45 (11.00-20.70)</td>
<td>16.50 (14.10-20.20)</td>
<td>15.80 (13.60-19.80)</td>
<td>9.30 (7.80-14.00)</td>
<td>8.10 (6.00-13.10)</td>
<td>8.15 (6.30-9.00)</td>
<td>8.25 (6.70-9.80)</td>
</tr>
<tr>
<td>3</td>
<td>7.22 (6.30-8.40)</td>
<td>15.50 (13.20-22.00)</td>
<td>15.55 (13.00-20.00)</td>
<td>14.70 (12.50-17.00)</td>
<td>8.50 (6.80-11.00)</td>
<td>6.95 (6.00-8.30)</td>
<td>7.15 (6.20-7.90)</td>
<td>6.85 (6.00-7.00)</td>
</tr>
<tr>
<td>4</td>
<td>7.77 (7.00-8.25)</td>
<td>18.05 (16.60-24.00)</td>
<td>16.95 (14.80-22.00)</td>
<td>15.90 (14.90-19.90)</td>
<td>11.35 (9.30-13.00)</td>
<td>7.75 (7.20-9.70)</td>
<td>7.70 (7.00-9.00)</td>
<td>7.45 (6.90-8.00)</td>
</tr>
<tr>
<td>5</td>
<td>7.90 (6.25-8.10)</td>
<td>17.75 (16.00-21.00)</td>
<td>17.35 (15.30-24.00)</td>
<td>16.75 (15.00-18.50)</td>
<td>11.10 (10.00-18.70)</td>
<td>7.90 (7.00-8.70)</td>
<td>7.85 (6.50-8.30)</td>
<td>7.45 (6.10-8.00)</td>
</tr>
</tbody>
</table>

### Table 2. Tail-flick test reaction times (in sec) for 5 days in dexmedetomidine-administered rats

<table>
<thead>
<tr>
<th>Day</th>
<th>Baseline</th>
<th>5 min</th>
<th>10 min</th>
<th>20 min</th>
<th>30 min</th>
<th>40 min</th>
<th>60 min</th>
<th>90 min</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>median (min-max)</td>
<td>median (min-max)</td>
<td>median (min-max)</td>
<td>median (min-max)</td>
<td>median (min-max)</td>
<td>median (min-max)</td>
<td>median (min-max)</td>
<td>median (min-max)</td>
</tr>
<tr>
<td>1</td>
<td>5.22 (4.40-5.50)</td>
<td>9.20 (8.30-10.50)</td>
<td>9.85 (7.90-13.20)</td>
<td>8.40 (7.00-9.70)</td>
<td>6.25 (5.00-7.40)</td>
<td>5.90 (5.00-7.00)</td>
<td>5.15 (4.00-6.88)</td>
<td>4.65 (4.00-6.20)</td>
</tr>
<tr>
<td>2</td>
<td>3.65 (2.75-5.15)</td>
<td>6.45 (5.80-10.30)</td>
<td>7.20 (6.00-10.90)</td>
<td>7.05 (5.70-9.70)</td>
<td>4.75 (4.00-6.70)</td>
<td>4.00 (3.00-5.00)</td>
<td>3.70 (3.00-5.00)</td>
<td>3.55 (3.00-4.90)</td>
</tr>
<tr>
<td>3</td>
<td>3.07 (2.85-3.90)</td>
<td>6.95 (6.20-8.00)</td>
<td>6.35 (6.20-8.00)</td>
<td>6.45 (6.00-7.70)</td>
<td>3.60 (3.00-5.10)</td>
<td>3.15 (3.00-4.00)</td>
<td>3.20 (2.50-3.50)</td>
<td>2.85 (2.50-3.50)</td>
</tr>
<tr>
<td>4</td>
<td>3.47 (3.10-4.10)</td>
<td>7.10 (6.50-8.10)</td>
<td>7.20 (6.70-8.00)</td>
<td>7.20 (6.40-8.20)</td>
<td>5.15 (4.60-6.70)</td>
<td>3.85 (3.60-5.00)</td>
<td>3.25 (3.00-3.70)</td>
<td>3.25 (3.10-3.70)</td>
</tr>
<tr>
<td>5</td>
<td>3.52 (3.24-3.75)</td>
<td>7.65 (7.20-7.80)</td>
<td>7.45 (7.30-7.90)</td>
<td>7.25 (6.90-7.50)</td>
<td>4.90 (4.20-5.20)</td>
<td>4.10 (4.00-4.90)</td>
<td>3.75 (3.00-4.30)</td>
<td>3.45 (3.10-4.20)</td>
</tr>
</tbody>
</table>
Similar rates of nonspecific changes such as edema and gliosis were seen in both groups. Signs of severe reactions such as neuronal degeneration and diffuse inflammatory cell infiltration were not encountered in any group (Figures 1-4). According to histopathological findings of both regions of the spinal cord, no significant intergroup difference was detected on the 6th or the 21st day (p>0.05) (Tables 3, 4).

**Discussion**

Compared with other alpha2 agonists, dexmedetomidine has a higher receptor specificity, selectivity, and potentially increased analgesic efficacy. Therefore, it can be an ideal adjuvant to local anaesthetics in neuroaxial blocks. The analgesic effect of dexmedetomidine has been investigated in many

<table>
<thead>
<tr>
<th>Changes</th>
<th>6th Day</th>
<th>21st Day</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Group D (n=8)</td>
<td>Group C (n=7)</td>
</tr>
<tr>
<td>Nonspecific changes</td>
<td>5 (63%)</td>
<td>6 (86%)</td>
</tr>
<tr>
<td>Mild changes</td>
<td>3 (37%)</td>
<td>1 (14%)</td>
</tr>
<tr>
<td>Markedly severe changes</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>p</td>
<td>0.119</td>
<td>0.200</td>
</tr>
</tbody>
</table>
In previous studies, Fisher et al. (18) detected significantly prolonged latencies in hot plate and tail-flick tests in rats that received intrathecal dexmedetomidine at doses of 3 and 10 µg. Joo et al. (19) evaluated the analgesic effectiveness of intrathecal 0.3, 1, 3, and 10 µg dexmedetomidine in rats by means of the tail-flick test, and observed a dose-related effect that started at a dose of 3 µg. They also demonstrated sedation-induced effects with the same doses. Kalso et al. (20) delivered dexmedetomidine via the intrathecal route to rats at doses of 1.5, 3, and 6 µg, and evaluated its antinociceptive effectiveness using the tail-flick test. They detected the onset of antinociceptive effect at a dose of 3 µg. Kanazi et al. (21) added 3 µg dexmedetomidine or 30 µg clonidine to intrathecal 12 mg bupivacaine for patients undergoing transurethral resection of prostate or bladder tumour. They concluded that 3 µg dexmedetomidine and 30 µg clonidine prolonged sensory and motor block duration. Al-Mustafa et al. (22) added 5 µg or 10 µg dexmedetomidine to intrathecal 12.5 mg bupivacaine for patients undergoing transurethral resection of prostate or bladder tumour, or placement of tension-free vaginal tape for urinary incontinence control. They concluded that dexmedetomidine reduced the onset and prolonged the duration of sensory and motor block. Mohamed et al. (23) found that addition of 5 µg dexmedetomidine to 10 mg bupivacaine intrathecally in patients before major abdominal cancer surgery improved the duration and quality of postoperative analgesia. In a previous study, Xiang et al. (24) added dexmedetomidine to bupivacaine in 60 children aged 1-6 years. Thirty children received 1 mL/kg volume of 0.25% bupivacaine plus 1 µg/kg dexmedetomidine caudally. Other children received 1 mL/kg of 0.25% bupivacaine. They concluded that addition of dexmedetomidine to bupivacaine caudally reduced the response to hernial sac traction and improved the duration of postoperative analgesia. In our study, we used the lowest effective analgesic dose of dexmedetomidine, 3 µg (approximately 10 µg/kg), and similarly detected that this dose-induced significant increase in latent periods, as evaluated by the tail-flick and hot plate tests. The reaction times at 90 min on the first day, at 60 min on the second day, at 40, 60, and 90 min on the third day, and at 90 min on the fifth day in hot plate tests were shorter than baseline values. A shorter reaction time compared with baseline values depends on the learning phenomena of rats (25).

Although dexmedetomidine is not effective on the neuromuscular junction, it exerts a central effect on muscles, like benzodiazepines. It can provide muscular relaxation via central pathways without affecting the neuromuscular junction (26). Similarly, we observed the loss of stepping and righting reflexes in rats that received intrathecal dexmedetomidine. However, this effect might be related to decreased muscular tone secondary to sedation and the central effects of dexmedetomidine.

Dexmedetomidine exerts its anxiolytic and sedative effects via activation of alpha2 adrenoceptors in the locus coeruleus, which is the major adrenergic innervation area in the central nervous system. Dexmedetomidine can provide sedoanalgesia especially without inducing respiratory depression. It is a potent selective alpha agonist with sedative, analgesic, and anxiolytic properties (27). Burkle et al. (28) administered three different alpha adrenergic agonists to rats, i.e., dexmedetomidine, clonidine, and UK-14.304 via the intracerebroventricular route, at doses of 3-10 µg, 10-100 µg, and 3-30 µg, and detected stronger sedative effects of dexmedetomidine compared with the other agonists. In our study, we also observed a prominent sedative effect with 3 µg dexmedetomidine, which developed very rapidly and immediately after intracerebroventricular administration of the drug.

Drugs directly administered through the intrathecal route carry risks of central nervous system damage and neurotoxicity. Safe usage of intrathecally administered drugs requires unequivocal disclosure of their effects on the central nervous system. In rats that received only physiological saline injections through an intrathecal catheter, numerous mononuclear inflammatory cells in the regions adjacent to the leptomeninx along the course of the catheter were seen, while inflammatory cell infiltration occurred less frequently in rats that were only catheterised (29). Therefore, we preferred to use the intracerebroventricular catheterisation technique, which has no direct contact with the spinal cord in order to prevent the occurrence of potential histopathological adverse effects (fibrosis and lymphocytic infiltration) secondary to the implantation of an intrathecal catheter.

This study has several limitations. We administered dexmedetomidine intracerebroventricularly; furthermore, it was not shown that dexmedetomidine reached the spinal area, and no samples were obtained from the locus coeruleus for histopathological evaluation. Thus, although neurotoxicity was not observed in the spinal cord it does not mean that it was not present in other parts of the nervous system and ventricular system.

In previous studies, with intrathecal administration of higher doses of the alpha2 agonist clonidine, no neurotoxic

<table>
<thead>
<tr>
<th>Changes</th>
<th>6th Day</th>
<th>21st Day</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Group D (n=8)</td>
<td>Group C (n=7)</td>
</tr>
<tr>
<td>Nonspecific changes</td>
<td>6 (75%)</td>
<td>6 (86%)</td>
</tr>
<tr>
<td>Mild changes</td>
<td>2 (25%)</td>
<td>1 (14%)</td>
</tr>
<tr>
<td>Markedly severe changes</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>p</td>
<td>1.000</td>
<td></td>
</tr>
</tbody>
</table>
effects on the spinal cord or nerve roots were encountered (29, 30). Konakci et al. (31) revealed demyelination of oligodendrocytes in the white matter of the spinal cord after epidural administration of 5 and 10 μg dexmedetomidine. Although histopathological evaluation was performed immediately after administration of dexmedetomidine and 1 day following epidural catheterisation, this study lacked a saline control group. Tachibana et al. (32) administered dexmedetomidine at doses of 5 and 10 μg/kg i.p. in rat pups to clarify the long-term neurological results. They demonstrated that these doses were enough for long-term elevation of plasma dexmedetomidine concentration. Their findings suggest that dexmedetomidine at doses of 5 and 10 μg/kg does not impair hippocampal synaptic activity after maturation. Gu et al. (33) evaluated the neuroprotective effects of dexmedetomidine in a rat spinal cord injury model. Their findings suggest that i.p. 10 μg/kg dexmedetomidine may have a neuroprotective effect by inhibition of lipid peroxidation in spinal cord injury. Zhu et al. (34) found that intravenous administration of 15 μg/kg dexmedetomidine protected the brain against focal cerebral ischaemia/reperfusion in rats after middle cerebral artery occlusion. They concluded that dexmedetomidine decreased the neurological deficit score, brain edema, cerebral infarct volume, and neuronal death. Brummet et al. (35) added dexmedetomidine to bupivacaine for sciatic nerve block in rats to evaluate its neurotoxic effect. In their study, they used higher doses (28-40 μg/kg) of dexmedetomidine. They performed histopathological evaluations at 24 hours, and 14 days later and demonstrated that all of the nerves had normal axons and myelin. In the present study, we also did not encounter any finding to suggest the neurotoxicity of dexmedetomidine.

In conclusion, intracerebroventricular administration of 3 μg dexmedetomidine in rats induces antinociceptive and sedative effects without any neurotoxic impact on the spinal cord.

Ethics Committee Approval: Ethics committee approval was received for this study (22.01.2008-OMU-HADYEK/08).

Informed Consent: N/A

Peer-review: Externally peer-reviewed.


Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

References

2. D’Angelo R. Should we administer epidural or spinal clonidine during labor? Reg Anesth Pain Med 2000;25:3-4. [CrossRef]
4. Khan ZP, Ferguson CN, Jones RM. Alpha-2 and imidazoline receptor agonists. Their pharmacology and therapeutic role. Anesthesia 1999;54:146-165. [CrossRef]
5. Lakhiani PP, MacMillan LB, Guo TZ. Substitution of a mutant alpha2 adrenergic receptor via “hit and run” gene targeting reveals the role of this subtype in sedative, analgesic, and anesthetic-sparing responses in vivo. Proc Natl Acad Sci 1997;94:9950-5. [CrossRef]


25. Espejo EF, Mir D. Structure of the rat’s behaviour in the hot plate test. Behav Brain Res 1993;56:171-6. [CrossRef]


27. Venn RM, Karol MD, Grounds RM. Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive care. Br J Anaesth 2002;88:669-75. [CrossRef]


